Achiko AG (ACHKF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Achiko AG (ACHKF) with AI Score 46/100 (Weak). Achiko AG is a healthcare company focused on developing diagnostic solutions, including the AptameX rapid Covid-19 test and the Teman Sehat mobile application. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Achiko AG (ACHKF) Healthcare & Pipeline Overview
Achiko AG is a Swiss-based healthcare company specializing in disruptive diagnostic solutions, including the AptameX rapid COVID-19 test utilizing DNA aptamers. The company also offers the Teman Sehat mobile health passport and Mimopay, a secure payment platform for digital content, operating primarily in Indonesia and internationally.
Investment Thesis
Achiko AG presents a high-risk, high-reward investment opportunity in the healthcare and digital solutions space. The company's AptameX rapid COVID-19 test offers potential as a disruptive diagnostic tool, although its market acceptance and regulatory approvals remain uncertain. The Teman Sehat mobile application could gain traction as a health passport solution, particularly in regions with evolving public health requirements. However, Achiko's financial performance, characterized by a negative profit margin of -14913.2% and a small market capitalization, indicates significant challenges. The company's success hinges on its ability to successfully commercialize its products, secure funding, and navigate a competitive landscape. Investors should carefully consider the risks associated with Achiko's OTC listing and limited financial disclosure.
Based on FMP financials and quantitative analysis
Key Highlights
- Achiko AG operates with a small team of 10 employees, indicating a lean operational structure.
- The company's lead product, AptameX, is a rapid test for SARS-CoV-2 using DNA aptamers, potentially offering a faster and more cost-effective diagnostic solution.
- Achiko's gross margin stands at 37.3%, reflecting the potential profitability of its diagnostic and digital solutions.
- The company's negative P/E ratio of -0.04 and profit margin of -14913.2% highlight its current financial challenges.
- Achiko AG's beta of -0.39 suggests a low correlation with the overall market, potentially offering some diversification benefits.
Competitors & Peers
Strengths
- Innovative AptameX technology for rapid COVID-19 testing.
- Teman Sehat mobile app addresses the need for digital health solutions.
- Mimopay provides a secure payment platform for digital content.
- Geographic focus on Indonesia and international markets.
Weaknesses
- Limited financial resources and small market capitalization.
- Negative profit margin and reliance on external funding.
- OTC listing with limited liquidity and disclosure requirements.
- Dependence on the success of a few key products.
Catalysts
- Upcoming: Regulatory approvals for AptameX in key markets, potentially expanding its commercial reach.
- Upcoming: Strategic partnerships with healthcare providers or distributors to increase AptameX sales.
- Ongoing: Continued adoption of Teman Sehat mobile app by organizations and government agencies.
- Ongoing: Expansion of Mimopay payment solutions to new digital content providers.
- Ongoing: Development of new diagnostic tests based on the AptameX technology.
Risks
- Potential: Competition from established healthcare companies and diagnostic providers.
- Potential: Regulatory hurdles and delays in obtaining approvals for AptameX.
- Potential: Changes in public health policies and testing requirements.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: OTC listing with limited liquidity and disclosure requirements.
Growth Opportunities
- Expansion of AptameX Testing: Achiko has the opportunity to expand the market reach of its AptameX rapid COVID-19 test. The global market for COVID-19 diagnostics is expected to remain substantial, driven by ongoing testing needs and the emergence of new variants. Securing regulatory approvals in key markets and establishing distribution partnerships could significantly increase AptameX sales. The timeline for this growth opportunity is ongoing, as the pandemic continues to evolve and testing remains a critical tool for managing its spread.
- Adoption of Teman Sehat Mobile App: Achiko can capitalize on the growing demand for digital health solutions by promoting its Teman Sehat mobile application. As governments and organizations seek ways to manage public health and facilitate safe travel, Teman Sehat could gain traction as a health passport and check-in system. Partnering with airlines, event organizers, and government agencies could accelerate adoption. The timeline for this growth opportunity is near-term, as the need for digital health solutions persists.
- Diversification of Diagnostic Solutions: Achiko can leverage its AptameX technology to develop diagnostic tests for other infectious diseases and health conditions. Expanding its product portfolio beyond COVID-19 would reduce its reliance on a single market and create new revenue streams. The global diagnostics market is vast and growing, offering numerous opportunities for innovative testing solutions. The timeline for this growth opportunity is medium-term, as it requires research, development, and clinical validation.
- Strategic Partnerships and Acquisitions: Achiko can accelerate its growth by forming strategic partnerships with established healthcare companies or acquiring complementary businesses. Collaborations with larger players could provide access to wider distribution networks, regulatory expertise, and financial resources. Acquisitions could expand Achiko's product portfolio and technological capabilities. The timeline for this growth opportunity is ongoing, as Achiko continuously seeks opportunities to enhance its competitive position.
- Expansion of Mimopay Payment Solutions: Achiko can expand its Mimopay payment solutions to serve a wider range of digital content providers and application developers. The global market for digital payments is experiencing rapid growth, driven by the increasing adoption of online gaming, e-commerce, and mobile applications. By offering secure and convenient payment options, Mimopay can attract new customers and increase its transaction volume. The timeline for this growth opportunity is medium-term, as it requires ongoing investment in technology and marketing.
Opportunities
- Expansion of AptameX testing to new markets and applications.
- Increased adoption of Teman Sehat as a health passport solution.
- Diversification of diagnostic solutions beyond COVID-19.
- Strategic partnerships and acquisitions to accelerate growth.
Threats
- Competition from established healthcare companies and diagnostic providers.
- Regulatory hurdles and delays in obtaining approvals for AptameX.
- Changes in public health policies and testing requirements.
- Economic downturns and reduced consumer spending on digital content.
Competitive Advantages
- Proprietary AptameX technology using DNA aptamers for rapid diagnostics.
- First-mover advantage in developing a mobile health passport solution with Teman Sehat.
- Established relationships with game publishers and application developers through Mimopay.
- Geographic focus on Indonesia and international markets with specific local expertise.
About ACHKF
Achiko AG, incorporated in 2018 and headquartered in Zurich, Switzerland, is a healthcare company focused on developing and commercializing disruptive diagnostic solutions. The company's primary focus is on its AptameX technology, a rapid diagnostic test for the SARS-CoV-2 virus that utilizes DNA aptamers instead of traditional antibodies. This innovative approach aims to provide a faster and potentially more cost-effective testing solution. In addition to AptameX, Achiko offers Teman Sehat, a mobile application designed as a health passport and check-in system, particularly relevant in the context of pandemic management and public health monitoring. Beyond diagnostics, Achiko AG also operates Mimopay, a secure payment solution tailored for game publishers and application developers. Mimopay enables these businesses to accept a wide range of payment methods for digital content and goods. The company also engages in game software development, diversifying its revenue streams and leveraging its technological capabilities. Achiko's operations are primarily based in Indonesia and internationally, reflecting its strategy to address global healthcare and digital payment needs. The company's relatively small size, with approximately 10 employees, suggests a focus on strategic partnerships and efficient resource allocation to achieve its goals.
What They Do
- Develops the AptameX rapid test for detecting the SARS-CoV-2 virus using DNA aptamers.
- Offers the Teman Sehat mobile application for health passport and check-in functionalities.
- Provides Mimopay, a secure payment solution for game publishers and application developers.
- Enables acceptance of various payment methods for digital content and goods.
- Engages in game software development.
- Focuses on disruptive diagnostic solutions in Indonesia and internationally.
Business Model
- Generates revenue from the sale of AptameX rapid COVID-19 tests.
- Offers Teman Sehat as a subscription or licensing model for organizations and governments.
- Earns transaction fees from Mimopay payment processing for digital content and goods.
- Derives income from the sale of game software.
Industry Context
Achiko AG operates within the healthcare information services industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for efficient diagnostic and digital health solutions. The COVID-19 pandemic has accelerated the adoption of rapid testing and mobile health applications, creating opportunities for companies like Achiko. However, the industry is also highly competitive, with established players such as ALSE (Alseres Pharmaceuticals), AQQRF (AdvanCell Isotopes), FLURF (Flora Growth Corp), LNDZF (Landa App), and MSITF (MITS Inc) and numerous startups vying for market share. Achiko's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strategic partnerships.
Key Customers
- Healthcare providers and testing centers using AptameX for rapid COVID-19 detection.
- Organizations and government agencies implementing Teman Sehat for health monitoring and check-in.
- Game publishers and application developers utilizing Mimopay for secure payment processing.
- Consumers purchasing game software developed by Achiko.
Financials
Chart & Info
Achiko AG (ACHKF) stock price: Price data unavailable
Latest News
No recent news available for ACHKF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACHKF.
Price Targets
Wall Street price target analysis for ACHKF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ACHKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wern-Yi Goh
Managing
Wern-Yi Goh serves as Managing for Achiko AG, overseeing the company's strategic direction and operations. His background includes experience in managing small teams, as Achiko AG currently has 10 employees. Further details on his specific career history, education, and previous roles are not available in the provided data. However, his leadership is crucial for guiding Achiko AG through its development and commercialization efforts in the healthcare and digital solutions space.
Track Record: Due to limited information, Wern-Yi Goh's specific achievements and strategic decisions at Achiko AG cannot be comprehensively assessed. However, under his management, the company has focused on developing and promoting its AptameX rapid COVID-19 test, Teman Sehat mobile application, and Mimopay payment solutions. The success of these initiatives will be key to evaluating his long-term track record.
ACHKF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Achiko AG may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in ACHKF.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and wider bid-ask spreads compared to major exchanges.
- Lack of regulatory oversight and potential for fraud or manipulation.
- Unknown disclosure status and limited availability of financial information.
- Greater price volatility and susceptibility to market rumors.
- Potential for delisting or suspension of trading.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements (if available).
- Assess the company's management team and their track record.
- Research the company's products, services, and market position.
- Evaluate the company's competitive landscape and potential risks.
- Understand the company's capital structure and funding requirements.
- Consult with a qualified financial advisor before investing.
- Company is incorporated in Switzerland, a jurisdiction with established corporate governance standards.
- Achiko AG has a registered business address and contact information.
- The company is actively developing and marketing its products and services.
- Achiko AG has a website and social media presence.
- The company has announced partnerships and collaborations with other organizations.
Achiko AG Stock: Key Questions Answered
What does Achiko AG do?
Achiko AG is a healthcare company focused on developing and commercializing disruptive diagnostic and digital solutions. Its primary product is AptameX, a rapid test for detecting the SARS-CoV-2 virus using DNA aptamers. The company also offers Teman Sehat, a mobile application designed as a health passport and check-in system. Additionally, Achiko provides Mimopay, a secure payment solution for game publishers and application developers. The company operates primarily in Indonesia and internationally, targeting the healthcare and digital payment markets.
What do analysts say about ACHKF stock?
As of 2026-03-16, formal analyst coverage of ACHKF is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to the company's financial challenges. Growth considerations center on the successful commercialization of AptameX, adoption of Teman Sehat, and expansion of Mimopay. Investors should conduct their own independent research and consider the risks associated with investing in OTC stocks.
What are the main risks for ACHKF?
The main risks for ACHKF include its limited financial resources, reliance on external funding, and OTC listing with limited liquidity and disclosure requirements. The company faces competition from established healthcare companies and diagnostic providers, as well as regulatory hurdles in obtaining approvals for AptameX. Changes in public health policies and testing requirements could also impact the demand for its products. Investors should carefully consider these risks before investing in ACHKF.
What are the key factors to evaluate for ACHKF?
Achiko AG (ACHKF) currently holds an AI score of 46/100, indicating low score. Key strength: Innovative AptameX technology for rapid COVID-19 testing.. Primary risk to monitor: Potential: Competition from established healthcare companies and diagnostic providers.. This is not financial advice.
How frequently does ACHKF data refresh on this page?
ACHKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACHKF's recent stock price performance?
Recent price movement in Achiko AG (ACHKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative AptameX technology for rapid COVID-19 testing.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACHKF overvalued or undervalued right now?
Determining whether Achiko AG (ACHKF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACHKF?
Before investing in Achiko AG (ACHKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete.
- OTC market data may be less reliable than major exchange data.
- AI analysis is pending and may provide further insights.